JP2005508336A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005508336A5 JP2005508336A5 JP2003530690A JP2003530690A JP2005508336A5 JP 2005508336 A5 JP2005508336 A5 JP 2005508336A5 JP 2003530690 A JP2003530690 A JP 2003530690A JP 2003530690 A JP2003530690 A JP 2003530690A JP 2005508336 A5 JP2005508336 A5 JP 2005508336A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrrolidinyl
- piperazinyl
- alkyl
- morpholinyl
- pyridinyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 3-fluoropyrrolidinyl Chemical group 0.000 claims description 133
- 150000001875 compounds Chemical class 0.000 claims description 28
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 229910052736 halogen Inorganic materials 0.000 claims description 16
- 150000002367 halogens Chemical class 0.000 claims description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims description 14
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 13
- 125000004193 piperazinyl group Chemical group 0.000 claims description 12
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 10
- 229910052799 carbon Inorganic materials 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 7
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 150000001408 amides Chemical class 0.000 claims description 6
- 150000001412 amines Chemical class 0.000 claims description 6
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 150000003568 thioethers Chemical class 0.000 claims description 6
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 229910052731 fluorine Inorganic materials 0.000 claims description 5
- ZCCPVTVGEQLONB-UHFFFAOYSA-N 1-(1,3-dioxolan-2-yl)-n-methylmethanamine Chemical compound CNCC1OCCO1 ZCCPVTVGEQLONB-UHFFFAOYSA-N 0.000 claims description 4
- QAFODUGVXFNLBE-UHFFFAOYSA-N 1-methoxybutan-2-amine Chemical compound CCC(N)COC QAFODUGVXFNLBE-UHFFFAOYSA-N 0.000 claims description 4
- ZUUQKDDUUOFCNP-UHFFFAOYSA-N 2-(1,3-dioxolan-2-yl)-n-methylethanamine Chemical compound CNCCC1OCCO1 ZUUQKDDUUOFCNP-UHFFFAOYSA-N 0.000 claims description 4
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims description 4
- 125000004364 3-pyrrolinyl group Chemical group [H]C1=C([H])C([H])([H])N(*)C1([H])[H] 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 4
- RZVWBASHHLFBJF-UHFFFAOYSA-N methyl piperidine-4-carboxylate Chemical compound COC(=O)C1CCNCC1 RZVWBASHHLFBJF-UHFFFAOYSA-N 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 claims description 3
- AHVQYHFYQWKUKB-UHFFFAOYSA-N oxan-4-amine Chemical compound NC1CCOCC1 AHVQYHFYQWKUKB-UHFFFAOYSA-N 0.000 claims description 3
- IPBPLHNLRKRLPJ-UHFFFAOYSA-N oxan-4-ylmethanamine Chemical compound NCC1CCOCC1 IPBPLHNLRKRLPJ-UHFFFAOYSA-N 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 14
- 125000005647 linker group Chemical group 0.000 claims 10
- 239000000825 pharmaceutical preparation Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 230000002062 proliferating effect Effects 0.000 claims 8
- 125000003386 piperidinyl group Chemical group 0.000 claims 7
- 206010016654 Fibrosis Diseases 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000001153 fluoro group Chemical group F* 0.000 claims 5
- 208000030159 metabolic disease Diseases 0.000 claims 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 5
- 230000004761 fibrosis Effects 0.000 claims 4
- 210000003584 mesangial cell Anatomy 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 3
- 201000004681 Psoriasis Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 3
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 125000006309 butyl amino group Chemical group 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 208000002780 macular degeneration Diseases 0.000 claims 3
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 206010063209 Chronic allograft nephropathy Diseases 0.000 claims 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010061218 Inflammation Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 2
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 claims 2
- 208000031737 Tissue Adhesions Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010003246 arthritis Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000007882 cirrhosis Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 125000004663 dialkyl amino group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000004054 inflammatory process Effects 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 201000009925 nephrosclerosis Diseases 0.000 claims 2
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 230000029663 wound healing Effects 0.000 claims 2
- KDHWOCLBMVSZPG-UHFFFAOYSA-N 3-imidazol-1-ylpropan-1-amine Chemical compound NCCCN1C=CN=C1 KDHWOCLBMVSZPG-UHFFFAOYSA-N 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002837 carbocyclic group Chemical group 0.000 claims 1
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000002877 alkyl aryl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32581501P | 2001-09-27 | 2001-09-27 | |
| US32581901P | 2001-09-27 | 2001-09-27 | |
| PCT/US2002/030882 WO2003027102A1 (en) | 2001-09-27 | 2002-09-27 | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010013326A Division JP2010116411A (ja) | 2001-09-27 | 2010-01-25 | キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005508336A JP2005508336A (ja) | 2005-03-31 |
| JP2005508336A5 true JP2005508336A5 (cg-RX-API-DMAC7.html) | 2006-01-12 |
Family
ID=26985125
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003530690A Pending JP2005508336A (ja) | 2001-09-27 | 2002-09-27 | キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類 |
| JP2010013326A Pending JP2010116411A (ja) | 2001-09-27 | 2010-01-25 | キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010013326A Pending JP2010116411A (ja) | 2001-09-27 | 2010-01-25 | キナーゼ阻害物質としての３−（アリールアミノ）メチレン−１，３−ジヒドロ−２ｈ−インドール−２−オン類 |
Country Status (6)
| Country | Link |
|---|---|
| US (7) | US6765012B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1430048A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP2005508336A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002341881B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2461812C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003027102A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998046588A2 (en) * | 1997-04-11 | 1998-10-22 | Neorx Corporation | Compounds and therapies for the prevention of vascular and non-vascular pathologies |
| US20030153015A1 (en) * | 2000-01-20 | 2003-08-14 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| KR100600550B1 (ko) | 2000-10-20 | 2006-07-13 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| AU2002341881B2 (en) * | 2001-09-27 | 2008-05-08 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
| PE20040701A1 (es) * | 2002-07-23 | 2004-11-30 | Boehringer Ingelheim Pharma | Derivados de indolinona sustituidos en posicion 6 y su preparacion como medicamentos |
| US7169936B2 (en) | 2002-07-23 | 2007-01-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments |
| US7514468B2 (en) | 2002-07-23 | 2009-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions |
| DE10233366A1 (de) * | 2002-07-23 | 2004-02-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
| WO2005044788A1 (ja) | 2003-11-11 | 2005-05-19 | Eisai Co., Ltd. | ウレア誘導体およびその製造方法 |
| US20050101582A1 (en) * | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
| US20070224278A1 (en) | 2003-11-12 | 2007-09-27 | Lyons Robert T | Low immunogenicity corticosteroid compositions |
| DE602005011928D1 (de) | 2004-01-20 | 2009-02-05 | Allergan Inc | Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure |
| US7338536B2 (en) | 2004-02-27 | 2008-03-04 | L'oreal S. A. | N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof |
| FR2866879A1 (fr) * | 2004-02-27 | 2005-09-02 | Oreal | Para-phenylenediamine secondaire n-alkylaminee, composition de teinture des fibres keratiniques contenant une telle para-phenylenediamine, procedes mettant en oeuvre cette composition et utilisations |
| KR100629713B1 (ko) * | 2004-04-10 | 2006-09-29 | (주)아모레퍼시픽 | 펜타에리스리톨 유도체와 이의 제조방법, 및 이를포함하는 액정베이스 |
| US9498457B2 (en) | 2004-04-30 | 2016-11-22 | Allergan, Inc. | Hypotensive prostamide-containing biodegradable intraocular implants and related implants |
| US7771742B2 (en) * | 2004-04-30 | 2010-08-10 | Allergan, Inc. | Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods |
| US20050244458A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular neuropathies |
| WO2005107708A1 (en) | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Biodegradable intravitreal tyrosine kinase inhibitors implants |
| US8591885B2 (en) * | 2004-04-30 | 2013-11-26 | Allergan, Inc. | Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems |
| US8673341B2 (en) | 2004-04-30 | 2014-03-18 | Allergan, Inc. | Intraocular pressure reduction with intracameral bimatoprost implants |
| US8147865B2 (en) | 2004-04-30 | 2012-04-03 | Allergan, Inc. | Steroid-containing sustained release intraocular implants and related methods |
| US8119154B2 (en) | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| US8455656B2 (en) | 2004-04-30 | 2013-06-04 | Allergan, Inc. | Kinase inhibitors |
| US20050244472A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Intraocular drug delivery systems containing excipients with reduced toxicity and related methods |
| US8425929B2 (en) | 2004-04-30 | 2013-04-23 | Allergan, Inc. | Sustained release intraocular implants and methods for preventing retinal dysfunction |
| US7993634B2 (en) | 2004-04-30 | 2011-08-09 | Allergan, Inc. | Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods |
| US20050244463A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Sustained release intraocular implants and methods for treating ocular vasculopathies |
| US20070059336A1 (en) * | 2004-04-30 | 2007-03-15 | Allergan, Inc. | Anti-angiogenic sustained release intraocular implants and related methods |
| US20050244478A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Anti-excititoxic sustained release intraocular implants and related methods |
| US20050244461A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Controlled release drug delivery systems and methods for treatment of an eye |
| US7799336B2 (en) | 2004-04-30 | 2010-09-21 | Allergan, Inc. | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
| US8722097B2 (en) | 2004-04-30 | 2014-05-13 | Allergan, Inc. | Oil-in-water method for making polymeric implants containing a hypotensive lipid |
| US20050244462A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Devices and methods for treating a mammalian eye |
| US20050244471A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Estradiol derivative and estratopone containing sustained release intraocular implants and related methods |
| US20050244466A1 (en) * | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Photodynamic therapy in conjunction with intraocular implants |
| JP4834553B2 (ja) | 2004-09-17 | 2011-12-14 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 医薬組成物 |
| TW200640443A (en) | 2005-02-23 | 2006-12-01 | Alcon Inc | Methods for treating ocular angiogenesis, retinal edema, retinal ischemia, and diabetic retinopathy using selective RTK inhibitors |
| US7309787B2 (en) * | 2005-07-13 | 2007-12-18 | Allergan, Inc. | Kinase inhibitors |
| CA2602389A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Kinase inhibitors |
| AU2006268174A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Kinase inhibitors |
| US7749530B2 (en) | 2005-07-13 | 2010-07-06 | Allergan, Inc. | Kinase inhibitors |
| US9006240B2 (en) | 2005-08-02 | 2015-04-14 | Eisai R&D Management Co., Ltd. | Method for assay on the effect of vascularization inhibitor |
| US8367664B2 (en) * | 2006-01-24 | 2013-02-05 | Allergan, Inc. | Substituted 3-(5-membered unsaturated heterocyclyl-1, 3-dihydro-indol-2-one's and derivatives thereof as kinase inhibitors |
| US7977351B2 (en) | 2006-03-22 | 2011-07-12 | Allergan, Inc. | Heteroaryl dihydroindolones as kinase inhibitors |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| WO2008022013A1 (en) * | 2006-08-11 | 2008-02-21 | Allergan, Inc. | Kinase inhibitors |
| CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| US8558002B2 (en) | 2006-11-16 | 2013-10-15 | Allergan, Inc. | Sulfoximines as kinase inhibitors |
| US8143410B2 (en) | 2006-11-16 | 2012-03-27 | Allergan, Inc. | Kinase inhibitors |
| US8969415B2 (en) | 2006-12-01 | 2015-03-03 | Allergan, Inc. | Intraocular drug delivery systems |
| EP2119707B1 (en) | 2007-01-29 | 2015-01-14 | Eisai R&D Management Co., Ltd. | Composition for treatment of undifferentiated-type of gastric cancer |
| US8642067B2 (en) | 2007-04-02 | 2014-02-04 | Allergen, Inc. | Methods and compositions for intraocular administration to treat ocular conditions |
| US7911053B2 (en) * | 2007-04-19 | 2011-03-22 | Marvell World Trade Ltd. | Semiconductor packaging with internal wiring bus |
| EP2170827B1 (en) * | 2007-06-21 | 2013-08-14 | Janssen Pharmaceutica, N.V. | Indolin-2-ones and aza-indolin-2-ones |
| JP5209254B2 (ja) * | 2007-08-30 | 2013-06-12 | 日本曹達株式会社 | 置換フェノキシアザビシクロオクタン誘導体の製造方法 |
| WO2009060945A1 (ja) | 2007-11-09 | 2009-05-14 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質と抗腫瘍性白金錯体との併用 |
| US9340555B2 (en) | 2009-09-03 | 2016-05-17 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| US8809534B2 (en) | 2009-09-03 | 2014-08-19 | Allergan, Inc. | Compounds as tyrosine kinase modulators |
| JP5982287B2 (ja) | 2009-11-09 | 2016-08-31 | アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ | 発毛を刺激する組成物および方法 |
| AU2011270165B2 (en) | 2010-06-25 | 2015-12-24 | Eisai R&D Management Co., Ltd. | Antitumor agent using compounds having kinase inhibitory effect in combination |
| JP6021805B2 (ja) | 2011-04-18 | 2016-11-09 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| CN103304468A (zh) * | 2012-03-13 | 2013-09-18 | 华东师范大学 | 一种氧化吲哚的一锅法串联合成方法 |
| US9642851B2 (en) | 2012-12-06 | 2017-05-09 | Kbp Biosciences Co., Ltd. | Indolinone derivative as tyrosine kinase inhibitor |
| JPWO2014098176A1 (ja) | 2012-12-21 | 2017-01-12 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| HK1218850A1 (zh) | 2013-02-15 | 2017-03-17 | Allergan, Inc. | 持续药物递送植入物 |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| WO2014201587A1 (zh) * | 2013-06-20 | 2014-12-24 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 具有酪氨酸激酶抑制活性的物质、其制备方法及用途 |
| SMT202200367T1 (it) | 2014-08-28 | 2022-11-18 | Eisai R&D Man Co Ltd | Derivato di chinolina a elevata purezza e metodo per la produzione dello stesso |
| CA2976325C (en) | 2015-02-25 | 2023-07-04 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| CN107801379B (zh) | 2015-06-16 | 2021-05-25 | 卫材R&D管理有限公司 | 抗癌剂 |
| AU2016309356B2 (en) | 2015-08-20 | 2021-06-24 | Eisai R&D Management Co., Ltd. | Tumor therapeutic agent |
| ES2971448T3 (es) | 2017-02-08 | 2024-06-05 | Eisai R&D Man Co Ltd | Composición farmacéutica para el tratamiento de tumores |
| CN108822017A (zh) * | 2017-04-11 | 2018-11-16 | 中国医学科学院药物研究所 | 新型吲哚酮化合物及其制法和药物用途 |
| CA3061888A1 (en) | 2017-05-16 | 2018-11-22 | Eisai R&D Management Co., Ltd. | Treatment of hepatocellular carcinoma |
| WO2020070332A1 (en) * | 2018-10-05 | 2020-04-09 | Ichnos Sciences S.A. | Oxindole compounds for use as map4k1 inhibitors |
| CN111285872B (zh) * | 2018-12-06 | 2022-05-17 | 北京志健金瑞生物医药科技有限公司 | 吲哚-2-酮衍生物及其制备方法与用途 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4476307A (en) * | 1982-09-20 | 1984-10-09 | Pfizer Inc. | Heteroylidene indolone compounds |
| US4966849A (en) * | 1985-09-20 | 1990-10-30 | President And Fellows Of Harvard College | CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression |
| US5217999A (en) * | 1987-12-24 | 1993-06-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Styryl compounds which inhibit EGF receptor protein tyrosine kinase |
| AT389506B (de) * | 1988-08-04 | 1989-12-27 | Voest Alpine Maschinenbau | Verfahren und vorrichtung zum graphitieren von kohlenstoffkoerpern |
| ES2064101T3 (es) | 1990-04-02 | 1995-01-16 | Pfizer | Compuestos de acido bencilfosfonico inhibidores de la quinasa de tirosina. |
| US5302606A (en) * | 1990-04-16 | 1994-04-12 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase |
| WO1992020642A1 (en) | 1991-05-10 | 1992-11-26 | Rhone-Poulenc Rorer International (Holdings) Inc. | Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase |
| WO1992021660A1 (en) | 1991-05-29 | 1992-12-10 | Pfizer, Inc. | Tricyclic polyhydroxylic tyrosine kinase inhibitors |
| SK283413B6 (sk) | 1992-08-06 | 2003-07-01 | Warner-Lambert Company | 2-Tioindoly, 2-indolíntióny a polysulfidy, ich selénové analógy a farmaceutické prostriedky na ich báze |
| US5330992A (en) * | 1992-10-23 | 1994-07-19 | Sterling Winthrop Inc. | 1-cyclopropyl-4-pyridyl-quinolinones |
| WO1994010202A1 (en) | 1992-10-28 | 1994-05-11 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| GB9226855D0 (en) | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
| US6316635B1 (en) * | 1995-06-07 | 2001-11-13 | Sugen, Inc. | 2-indolinone derivatives as modulators of protein kinase activity |
| US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
| GB9718913D0 (en) * | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| DE19824922A1 (de) * | 1998-06-04 | 1999-12-09 | Boehringer Ingelheim Pharma | Neue substituierte Indolinone, ihre Herstellung und ihre Verwendung als Arzneimittel |
| JP2002523455A (ja) | 1998-08-31 | 2002-07-30 | スージェン・インコーポレーテッド | 蛋白質キナーゼ活性の調節剤としての幾何学的に制限された２−インドリノン誘導体 |
| HUP0104973A3 (en) * | 1998-09-25 | 2002-06-28 | Boehringer Ingelheim Pharma | Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes, process for their use and medicaments containing them |
| GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
| MXPA02002097A (es) * | 1999-08-27 | 2002-11-07 | Boehringer Ingelheim Pharma | Indolinas sustituidas como inhibidoras de la tirosina cinasa. |
| UA75054C2 (uk) * | 1999-10-13 | 2006-03-15 | Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг | Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу |
| US6762180B1 (en) * | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
| EP1339680A1 (en) * | 2000-09-01 | 2003-09-03 | Glaxo Group Limited | Substituted oxindole derivatives as tyrosine kinase inhibitors |
| AU2002341881B2 (en) * | 2001-09-27 | 2008-05-08 | Allergan, Inc. | 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors |
-
2002
- 2002-09-27 AU AU2002341881A patent/AU2002341881B2/en not_active Ceased
- 2002-09-27 CA CA2461812A patent/CA2461812C/en not_active Expired - Fee Related
- 2002-09-27 WO PCT/US2002/030882 patent/WO2003027102A1/en not_active Ceased
- 2002-09-27 US US10/256,879 patent/US6765012B2/en not_active Expired - Fee Related
- 2002-09-27 EP EP02776036A patent/EP1430048A1/en not_active Withdrawn
- 2002-09-27 US US10/259,703 patent/US20030225152A1/en not_active Abandoned
- 2002-09-27 JP JP2003530690A patent/JP2005508336A/ja active Pending
-
2004
- 2004-02-20 US US10/783,325 patent/US7015220B2/en not_active Expired - Lifetime
- 2004-07-06 US US10/886,213 patent/US7098236B2/en not_active Expired - Lifetime
-
2005
- 2005-09-16 US US11/228,780 patent/US20060025413A1/en not_active Abandoned
- 2005-11-15 US US11/274,681 patent/US7414054B2/en not_active Expired - Lifetime
-
2006
- 2006-03-31 US US11/396,036 patent/US20060194863A1/en not_active Abandoned
-
2010
- 2010-01-25 JP JP2010013326A patent/JP2010116411A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005508336A5 (cg-RX-API-DMAC7.html) | ||
| CA2461812A1 (en) | 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors | |
| US6090807A (en) | Use of heterocyclic compounds | |
| JP6728208B2 (ja) | ベンザゼピンジカルボキサミド化合物 | |
| US6232327B1 (en) | Indolyl-3-glyoxylic acid derivatives having antitumor action | |
| CN103124730B (zh) | 杂环炔苯类化合物及其药用组合物和应用 | |
| JP5886411B2 (ja) | 新規のピリミジン誘導体 | |
| RU2386630C2 (ru) | Соединения и композиции в качестве ингибиторов протеинтирозинкиназы | |
| RU2006137716A (ru) | Ингибиторы гистондеацетилазы | |
| RU2003115429A (ru) | Производные имида индолилмалеиновой кислоты как ингибиторы протеинкиназы с | |
| JP2019070044A (ja) | 医薬化合物 | |
| RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
| CA2529734A1 (en) | 2-amino-4-hydroxy-5-pyrimidine carboxamide derivatives and related compounds as inhibitors of t cell activation for the treatment of inflammatory diseases | |
| JP2012512886A5 (cg-RX-API-DMAC7.html) | ||
| JP2013526511A (ja) | 医薬化合物 | |
| JP2005508967A5 (cg-RX-API-DMAC7.html) | ||
| KR100674813B1 (ko) | Ｎ-페닐-2-피리미딘-아민 유도체 및 그의 제조방법 | |
| US11001581B2 (en) | Compounds which inhibit RNA polymerase, compositions including such compounds, and their use | |
| WO2013070657A1 (en) | Modulators of the g protein-coupled mas receptor and the treatment of disorders related thereto | |
| WO2009121535A2 (en) | Antiproliferative compounds and therapeutic uses thereof | |
| RU2009119181A (ru) | Гетероциклические соединения и их применение в качестве ингибиторов гликогенсинтаза-киназы-3 | |
| RU2149872C1 (ru) | Пиридилтиосоединения для борьбы с бактериями helicobacter | |
| US5308844A (en) | Substituted 3-piperazinylalkyl-2,3-dihydro-4H-1,3-benzoxazin-4-ones and their use in therapy | |
| RU2011105059A (ru) | Применение производных пиримидиламинобензамида для лечения фиброза | |
| CN111732548B (zh) | N2-氨甲酰芳环-2-氨基嘧啶类衍生物及其医药用途 |